hC Bioscience Appoints Cindy Driscoll as Senior Vice President of Finance to Lead Expanded Finance Team
Boston, Massachusetts--(Newsfile Corp. - September 14, 2023) - hC Bioscience announces the appointment of Cindy Driscoll to the new position of Senior Vice President of Finance. In this role, she will oversee the Company's financial strategy and lead the establishment of its finance and accounting team. As part of the appointment, hC Bioscience has added two additional members to its' financing and accounting team, Julie Harding as the Senior Director, Financial Planning & Analysis, and Casey Hill as the Accounting Manager. The expansion of the finance team reflects the Company's increased investment in preclinical development activities aimed at bringing tRNA-based therapeutics into the clinic.
To view the full announcement, including downloadable images, bios, and more, click here.
- hC Bioscience appointed Cindy Driscoll as Senior Vice President of Finance to lead the Company's financial strategy.
- As part of this appointment, the Company added two key hires to its finance team.
- The hires reflect hC Bioscience's increased investment in preclinical development activities aimed at bringing tRNA-based therapeutics into the clinic.
Click image above to view full announcement.
About hC Bioscience
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience's innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
Source: hC Bioscience
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/180602